The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib is used in the treatment of non–small cell lung cancer (NSCLC) patients harboring somatic EGFR mutations, including exon 19 deletion and exon 21 L858R substitution.1 The gene discussed is EGFR; the disease is lung cancer.